Cultivate Biologics' Breakfast Brief: New University Studies Show Efficacy of CBD/CBDA for Key Areas of Human Health

Despite continued regulatory challenges, the science behind full spectrum hemp, including CBD/CBDA, continues to show positive human health effects. Recent studies with university partners such as Johns Hopkins and Sonoran University demonstrate the efficacy and pharmacokinetic benefits, especially in the acidic form (CBDA).

Key Takeaways:
1. Results of 1,200 participant placebo controlled 4-week trial comparing full spectrum CBDA:CBD & CBDA extracts vs CBD isolate for anxiety, pain, sleep and overall well-being.
2. Early human dosing implications of full spectrum extracts w/THC levels < 0.3% relate pharmacokinetics to cognitive performance.
3. The in vitro effect of full spectrum acid rich cannabinoid extracts on neuronal gene expression with implications related to therapeutic efficacy at pharmacologically relevant doses.

Moderator: Beth Dresser, VP of Business Development, Cultivate Biologics

Presenters:

• Dr. Robby Davis, Senior Director of Research and Development, Cultivate Biologics
• Dr. Jeffrey Langland, Ph.D., joint faculty member, Southwest College of Naturopathic Medicine, now Sonoran University of Health Sciences
• Dr. Joe Wakshlag, chief medical officer for Ellevet Sciences and professor of Veterinary Medicine, Cornell University

Sponsored by: